Jazz Pharmaceuticals Enters into License Agreement with Zymeworks for Zanidatamab
By Ayush Saxena
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 26 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2740 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to bolster its late-stage oncology portfolio, Jazz Pharmaceuticals has signed a licensing agreement with Zymeworks for the development and commercialisation of zanidatamab, a HER2-targeted bispecific antibody...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS